

Enzon Pharmaceuticals Inc. Investor Relations Department 20 Kingsbridge Road Attn: Accounts Payable Piscataway, NJ 08854 United States

Visit IR website ☐ Sign-up for email alerts ☐ ☐

0.38
3:50 PM ET Aug 23, 2017
-0.01 <b>4</b> (2.564%)
0.38 - 0.40
0.22 - 0.50
32,510
16.804
44.220

<sup>&</sup>lt;sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

# **Company Profile**

Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products, namely, PegIntron ®, Sylatron ®, Macugen ® and CIMZIA ®. ... (more)

### **Stock Performance**



## Press Releases [View all]

May 1, 2014

Enzon Adopts Stockholder Rights Plan in an Effort to Protect Net Operating Loss Carryforwards

Apr 23, 2013

Enzon Concludes Review of Possible Asset
Sales, Sale of the Company; Announces
\$1.60 Special Dividend and Periodic Royalty
Dividends

Mar 18, 2013

Enzon Reports Fourth Quarter and Full Year 2012 Results

Dec 17, 2012

Enzon to Review Asset Sales, Sale of the Company

Nov 29, 2012

**Enzon Announces Special Dividend** 

#### Events [View all]

There are no events to display at this time. Please check back later.

### Financials [View all]

Mar 24, 2017 Annual Report (10-K)

May 12, 2017

Definitive Proxy Statement

Aug 10, 2017 Quarterly Report (10-Q)

Quartony Ropolit (10 Q

May 11, 2017

Quarterly Report (10-Q)

Nov 10, 2016

Quarterly Report (10-Q)

